ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1143

Reduced Hydrogen Sulfide Synthesis in the Joint, a New Player in the Pathogenesis of Osteoarthritis

Angela Vela-Anero1, Lucia Gato-Calvo2,3, Cristina Ruiz-Romero2,3, Rosa Meijide-Failde1, Francisco J. Blanco3 and Elena F. Burguera3,4, 1Grupo de Terapia Celular y Medicina Regenerativa. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade de A Coruña (UDC), A Coruña, Spain, 2Grupo de Bioingeniería Tisular y Terapia Celular (GBTTC-CHUAC). CIBER-BBN/ISCIII. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade de A Coruña (UDC), A Coruña, Spain, 3Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade de A Coruña (UDC), A Coruña, Spain, 4Grupo de Bioingeniería Tisular y Terapia Celular (GBTTC-CHUAC). CIBER-BBN/ISCIII. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade de A Coruña (UDC), A Coruna, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: chondrocytes, osteoarthritis and pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydrogen sulfide (H2S) is, next to NO and CO, the third endogenous gasotransmitter. It has been shown that in some pathologies, such as hypertension, cardiovascular disease or diabetes type II, H2S endogenous levels or biosynthesis are significantly reduced and that exogenous administration might be helpful. Previous experiments by our group have demonstrated that H2S releasing compounds have anti-inflammatory and anti-catabolic effects on IL1β-stimulted OA chondrocytes. Therefore our hypothesis in the present work was that OA patients might also have lower endogenous H2S levels.

Methods: Joint tissues and blood samples were obtained from patients of the Orthopedic or Rheumatology Services of the University Hospital A Coruña (CHUAC), or volunteers (blood only), after written informed consent. The mRNA expression of the H2S production enzymes, cystathionine β-synthase (CBS), cystathionine γ-lyase (CTH) and mercaptopyruvate sulfurtransferase (MPST) was analyzed in cartilage, synovial membrane and subchondral bone. Immunohistochemistry and quantification with ImageJ was performed to evaluate the location and abundance of the CBS, CTH and MPST. Hydrogen sulfide concentration was measured using a selective ion microelectrode. Direct H2S concentration was measured in 200 μL of fresh serum after incubation with 200 μL of an antioxidant buffer (AB) for 1h. Likewise, H2S production from cartilage was measured by incubating cartilage disks in 200 μL of the same AB for 2 h.

Results: We found that all three enzymes, CBS, CTH and MPST were expressed in all tested joint tissues. CBS was slightly reduced in the OA cartilage, but no statistically significant differences were detected for this enzyme, nor CTH, in any tissue. Notably, however, MPST mRNA expression was significantly reduced in OA cartilage with respect to normal controls. Immunohistochemistry also showed decreased levels of this enzyme in cartilage. On the other hand, statistically significant differences were also found in the H2S production measured from OA with respect to non OA cartilage samples. Indeed, OA cartilage H2S production was 0.105 ± 0.042 nmoles/g of cartilage (mean ± SE, n=13) in OA tissue while that of healthy cartilage was 0.433 ± 0.110 nmoles/g of cartilage (mean ± SE, n=5), p<0.05. These differences, however, were not reflected in the H2S concentrations in blood serum samples, where no statistically significant differences were found (OA serum: 56.48 ± 7.24 μM (mean ± SE, n=38) vs. N serum: 72.18 ± 10.66 μM (mean ± SE, n=28), p>0.05).

Conclusion: Local H2S biosynthesis is reduced in the OA joint. This is the result, at the least, of a reduced mRNA expression and protein abundance of MPST. Since MPST is predominantly a mitochondrial enzyme, this deficit might be another factor that causes the mitochondrial dysfunction that is known to contribute to OA pathogenesis.


Disclosure: A. Vela-Anero, None; L. Gato-Calvo, None; C. Ruiz-Romero, None; R. Meijide-Failde, None; F. J. Blanco, Pfizer, Bioiberica, and Gebro Pharma, 5; E. F. Burguera, None.

To cite this abstract in AMA style:

Vela-Anero A, Gato-Calvo L, Ruiz-Romero C, Meijide-Failde R, Blanco FJ, Burguera EF. Reduced Hydrogen Sulfide Synthesis in the Joint, a New Player in the Pathogenesis of Osteoarthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/reduced-hydrogen-sulfide-synthesis-in-the-joint-a-new-player-in-the-pathogenesis-of-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-hydrogen-sulfide-synthesis-in-the-joint-a-new-player-in-the-pathogenesis-of-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology